Stockscreener 앱 받기
1.71
1.16%
-0.02
시장 영업 전:
1.77
0.06
+3.51%
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early - the deep dive
Cardiol Therapeutics Inc. (CRDL.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Inc. (CRDL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Slides Under Pressure: Clinical-Stage Uncertainty and Shelf Prospectus Overhang Weigh on Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Stock Price Target & Forecast - TradingKey
Cardiol Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co. - Moomoo
Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares - Kalkine Media
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9.00 - GuruFocus
Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares - Stock Titan
HC Wainwright & Co. reiterates Buy rating on Cardiol Therapeutics, $9 price target - TradingView
Cardiol expands phase III trial enrollment to 150 patients By Investing.com - Investing.com Nigeria
Cardiol Therapeutics (CRDL) Advances MAVERIC Phase III Trial, Ma - GuruFocus
Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone - TipRanks
Cardiol expands phase III trial enrollment to 150 patients - Investing.com India
Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy - TradingView
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy - PR Newswire
Why Are Markets Watching Cardiol Therapeutics (TSX:CRDL) Midcap Shares? - kalkinemedia.com
Cardiol Therapeutics Inc. (TSX:CRDL): A Fresh Healthcare Stocks Catalyst Today - Kalkine Media
Cardiol Therapeutics Inc. (TSX:CRDL) Back In Focus For Growth Stocks Watchers - Kalkine Media
Cardiol Therapeutics Inc. (TSX:CRDL): Today's Cannabis Stocks Story - kalkinemedia.com
Cardiol Therapeutics (Nasdaq: CRDL) opens path to raise cash for heart drug trials - Stock Titan
Cardiol Therapeutics (CRDL) Raises $7M via Warrants, Extends Run - GuruFocus
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds - PR Newswire
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Declines 6.86% as Selling Pressure Builds - kalkine.ca
New conduct code at Cardiol Therapeutics (CRDL) tightens conflict, confidentiality and whistleblower rules - Stock Titan
WHY TerrAscend (TSX:TSND), Cardiol Therapeutics Inc. (TSX:CRDL), Vizsla Royalties (TSXV:VROY), Quarterhill (TSX:QTRH) and GoldMining (TSX:GOLD) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
CRDL: Phase III data readout and expansion into heart failure set the stage for broad market impact - TradingView
Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL) - Seeking Alpha
CRDL: Cardiol Therapeutics IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cardiol Therapeutics (TSX:CRDL) Slides 12.34% as Volatility Returns and Investors Reassess the Clinical-Stage Risk - kalkine.ca
Cardiol Therapeutics Stock Faces Renewed Pressure as Biotech Risk and Clinical Uncertainty Weigh on Sentiment - kalkine.ca
Cardiol Therapeutics (CRDL) sets terms with new manufacturing and drug ingredient partners - Stock Titan
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus - TradingView
Cardiol Therapeutics files $150 million shelf prospectus - investing.com
New 25‑month shelf lets Cardiol Therapeutics (CRDL) line up future financing - Stock Titan
Cardiol Therapeutics files US$150M base shelf prospectus - tradingview.com
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission - PR Newswire
Cardiol Therapeutics Inc. (NASDAQ: CRDL) to Host Fireside Chat on September 14 at H.C. Wainwright Investment Conference - Kalkine Media
Cardiol Therapeutics (NASDAQ: CRDL) lines up new shelf to fund drug trials - Stock Titan
Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln - tradingview.com
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Gains Momentum as Cardiovascular Drug Pipeline Progress Strengthens Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Healthcare Stock Latest Update - Kalkine Media
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Heart-drug developer Cardiol Therapeutics (CRDL) heads to a major New York investor conference - Stock Titan
Cardiol Therapeutics will join a heart-disease drug chat in New York Sept. 14 - Stock Titan
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cardiol Therapeutics to present at H.C. Wainwri... - Pluang
Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research
Cardiol Therapeutics Inc Class A (CRDL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cardiol Therapeutics Inc Class A (CRDL) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca
0.18%
0.69%
자본화:
|
볼륨(24시간):